Currently Viewing:
Currently Reading
OlympiAD Trial Reports Success With Olaparib and Predictive Diagnostic Test
February 19, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: February 17, 2017
February 17, 2017
Experimental Treatment Induces Remission in Multiple Sclerosis
February 16, 2017 – Laura Joszt
Postmenopausal Weight Loss Cuts Risk of Endometrial Cancer by Half
February 16, 2017 – Surabhi Dangi-Garimella, PhD
UCSF Researchers Identify Determinants of Coverage for Hereditary Cancer Panels
February 15, 2017 – Surabhi Dangi-Garimella, PhD
Breast Cancer Survivors Report More Cognitive Impairment After Chemotherapy
February 15, 2017 – Christina Mattina
Sustained Response to Immune Checkpoint Inhibitors Could Influence Standard of Care
February 14, 2017 – Surabhi Dangi-Garimella, PhD
Navigator Program Lowered Costs, Utilization for Elderly Cancer Patients
February 13, 2017 – Christina Mattina
Predicting Response to SCT in Patients With MDS
February 13, 2017 – Surabhi Dangi-Garimella, PhD

OlympiAD Trial Reports Success With Olaparib and Predictive Diagnostic Test

Surabhi Dangi-Garimella, PhD
The trial successfully improved progression-free survival and also tested a BRCA diagnostic test in patients with ovarian cancer.
A phase 3 trial evaluating olaparib (Lynparza) against standard of care chemotherapy in women with HER2-negative metastatic breast cancer has seen significant improvement in progression-free survival (PFS) with olaparib. Additionally, the trial has also reported that a BRCA diagnostic test could successfully identify positive responders to olaparib.

The trial, OlympiAD, is a randomized, multi-center study designed to study whether olaparib is safer and more effective than physicians’ choice of chemotherapy: capecitabine, vinorelbine, or eribulin. The trial, which has global sites, was conducted in 302 patients with HER2-negative metastatic breast cancer, with germline BRCA1/2 mutations. PFS was the primary trial end point; secondary endpoints included overall survival, time to second progression or death, objective response rate, and effect on health-related quality of life.

In a press release announcing the results, executive vice president of the Global Medicines  Development at AstraZeneca, which is developing the drug, said “These results are positive news for patients with BRCA-mutated metastatic breast cancer, a disease with a high unmet need, and are the first positive phase 3 data for a PARP inhibitor beyond ovarian cancer.”

The OlympiAD study also successfully tested BRACAnalysis CDx, an FDA-approved genetic test that detects BRCA mutations in patients with HER2-negative breast cancer. In this trial, BRACAnalysis CDx identified patients who responded to olaparib. Of the 302 patients in the study, 297 (98%) tested positive for germline BRCA1/2 mutations.

Johnathan Lancaster, MD, PhD, chief medical officer of Myriad Genetic Laboratories, which has developed the diagnostic test, said that BRACAnalysis CDx can inform clinical treatment decisions in metastatic breast cancer and “expand the patient population who can benefit from BRCA testing.”

BRACAnalysis CDx is the first laboratory-developed companion diagnostic (CD) test to be FDA- approved. It was approved as a CD for olaparib to be used in the fourth-line setting for patients with ovarian cancer in 2014.

AstraZeneca is working toward submitting olaparib for an FDA review.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up